May 14, 2008Solvay launches new product for air pollution control Investing USD 40 Million in Innovative Technology to Manufacture SOLVAir ® Select 300 for Flue Gas Treatment [EN]-[FR]-[NL]
May 13, 2008Annual Shareholders Meeting 2008 Speeches by the Chairmen - Toespraken van de Voorzitters - Discours des Présidents [EN]-[FR]-[NL]
May 13, 2008First quarter 2008 results Operating results for the Solvay Group in the 1st quarter of 2008 : -8% compared to the high level of the 1st quarter of 2007. An increase of 12% compared to the 4th quarter of 2007. Net income of the Group (eur 220 million) up by 1%. [EN]-[FR]-[NL]
May 08, 2008Solvay to power its Bernburg (Germany) plant with secondary solid fuels Energy generated from Refuse Derived Fuel Available in 2010 [EN]-[FR]-[NL]
April 25, 2008SOLVAY PHARMACEUTICALS S.A. LAUNCHES FRIENDLY BID TO ACQUIRE INNOGENETICS Building on a successful R&D co-operation [EN]-[FR]-[NL]
March 31, 2008Phase III studies of investigational Trilipix™ (SLV348/ABT-335), in combination with statins, meets primary endpoints on improving LDL, triglycerides and HDL TriLipix™ in combination with statins improved all three key lipids and had reported safety consistent
with TriLipix™ or statin monotherapies
[EN]-[FR]-[NL]
March 12, 2008FDA approval of Abbott's SIMCOR® marks start of co-promotion with Solvay FDA Decision Triggers Milestone Payment of USD 100 million by Solvay to Abbott [EN]-[FR]-[NL]
March 06, 2008Solvay finalized sale of polypropelene compounding activity to Lyondellbasell Solvay announces today that it has finalized the sale of 100% of its subsidiary Solvay Engineered Polymers (SEP), a major supplier of polypropylene compounds, to LyondellBasell Industries. [EN]-[FR]-[NL]
March 03, 2008Fournier Laboratories Ireland Ltd and Laboratoires Fournier SA filed patent infringement actions against Teva in the USA Fournier Laboratories asserts intellectual property of TriCor® (fenofibrate) 145mg NFE [EN]-[FR]-[NL]
February 29, 2008Solvay Pharmaceuticals S.A. acknowledges decision of Wyeth Pharmaceuticals to terminate the collaboration agreement on bifeprunox Solvay Pharmaceuticals will evaluate all options for the future of the compound [EN]-[FR]-[NL]
